BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
KEYTRUDA (pembrolizumab) by Merck & Co. is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2014.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEYTRUDA (pembrolizumab) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1), unleashing the immune system to attack cancer cells. It is approved across multiple oncology indications and represents a foundational immunotherapy in modern cancer treatment. The drug works by preventing cancer cells from hiding from immune surveillance.
$0.117BPart D
PeakStable
Flagship immunotherapy at peak commercial maturity with 28 linked jobs; strong commercial infrastructure supports brand management and field sales roles.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Started Jun 2027
820 enrolled
Gastric CancerGastroesophageal-junction CancerAdvanced Cancer
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Started Dec 2026
60 enrolled
Squamous Non-Small Cell Lung Cancer (NSCLC)
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Started Dec 2026
18 enrolled
Metastatic Urothelial CarcinomaUrothelial CarcinomaLocally Advanced Urothelial Carcinoma+2 more
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
Started Nov 2026
150 enrolled
Neoplasm MalignantGastric NeoplasmsGastroesophageal Junction Adenocarcinoma+2 more
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Started Oct 2026
400 enrolled
Bladder Cancer
Worked on KEYTRUDA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.